Nu Skin guidance
This article was originally published in The Rose Sheet
Executive SummaryThird quarter revenue expected to increase 13% to $282 mil., with earnings per share likely to grow about 50% to $.27-$.28, or 20% excluding the impact of a $.04 per share one-time charge in the quarter, firm says during Oct. 4 analyst call. While U.S. sales are expected to grow about 25% year-over-year driven by Pharmanex division, direct-seller's results in Japan and China will be "softer than expected," President and CEO Truman Hunt says. Japanese sales are expected to fall 8% versus the year-ago period, while China's sales volume will be down about 4% compared to the previous quarter, with sales in the region expected to be $26 mil.-$27 mil. Chinese business is struggling in anticipation of new direct sales regulations, which may not be implemented until the second or third quarter of 2005, Hunt says...
You may also be interested in...
Phase III data earns a breakthrough therapy designation for Resverlogix’ apabetalone; previous companies to follow that strategy swiftly advance to NDA submission, as seen with Novartis’ capmatinib and Seattle Genetics’ tucatinib.
Pink Sheet analysis finds that evidence from early-stage trials supports most BTD requests, but about three in 10 designations are granted on the basis of pivotal-stage data.
Four House hearings show how far away even many Democrats are from supporting a single payer system in the US.